Table 1.

Summary of study design including Medicaid eligibility requirements for mothers and offspring, duloxetine exposure windows, outcome assessment windows, and covariate assessment windows

Cohort and outcome	Medicaid eligibility requirement: mother	Medicaid eligibility requirement: offspring	Duloxetine exposure window	Outcome assessment window	Covariate assessment window
Cohort 1:
Congenital malformations	90 days before LMP to 30 days after delivery	3 months after delivery (unless died)	Dispensed in first trimester	Delivery to 3 months after delivery	90 days before LMP to end of first trimester
Early exposure
Cohort 2:
Preterm birth	90 days before LMP to 30 days after delivery	1 month after delivery (unless died)	Dispensed LMP to LMP+140	Delivery to 1 month after delivery	90 days before LMP to LMP+140
Small for gestational age infant	90 days before LMP to 30 days after delivery	1 month after delivery (unless died)	Dispensed LMP to LMP+140	Delivery to 1 month after delivery	90 days before LMP to LMP+140
Cohort 3:
Pre-eclampsia	90 days before LMP to 30 days after delivery	None	Dispensed LMP to LMP+140	Delivery admission	90 days before LMP to LMP+140
Late exposure
Cohort 2:
Preterm birth	90 days before LMP to 30 days after delivery	1 month after delivery (unless died)	Dispensed LMP+141 to LMP+245	Delivery to 1 month after delivery	90 days before LMP to LMP+245
Small for gestational age infant	90 days before LMP to 30 days after delivery	1 month after delivery (unless died)	Dispensed LMP+141 to LMP+245	Delivery to 1 month after delivery	90 days before LMP to LMP+245
Cohort 3:
Pre-eclampsia	90 days before LMP to 30 days after delivery	None	Dispensed LMP+141 to LMP+245	Delivery admission	90 days before LMP to LMP+245
Cohort 4:
Postpartum hemorrhage	4 months before delivery to 1 month after delivery	None	Dispensed 1 month before delivery to delivery	Delivery admission	4 months before delivery to 1 day before delivery

LMP=last menstrual period.